GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Sample GSM3564252 Query DataSets for GSM3564252
Status Public on Sep 13, 2019
Title in situ Hi-C in RWPE1 rep1
Sample type SRA
Source name in situ Hi-C in RWPE1
Organism Homo sapiens
Characteristics cell line: RWPE1
cell type: Human normal prostate cell line
Growth protocol The human prostate cancer C42B cells were obtained from ViroMed Laboratories (Minneapolis, MN, USA) whereas the human prostate cancer 22Rv1 (ATCC # CRL-2505) and normal prostate RWPE1 (ATCC # CRL-11609) cells were obtained from ATCC ( Cells were grown at 37ºC in 5% CO2; the corresponding culture medium for each cell line (RPMI 1640 for C42B and 22Rv1 and Keratinocyte Serum Free Medium for RWPE-1) was supplemented with 10% fetal bovine serum (Gibco by Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin and streptomycin. All cell stocks were authenticated at the USC Norris Cancer Center cell culture facility by comparison to the ATCC and/or published genomic criteria for that specific cell line; all cells were documented as free of mycoplasma.
Extracted molecule genomic DNA
Extraction protocol In situ Hi-C experiments were performed following the original protocol by Rao et al with minor modifications. In situ Hi-C was performed in duplicate and 5 x 106 cells were used for each experiment. 100U of MboI restriction enzyme (NEB, R0147) was used to digest chromatin. For ligation, 2000U T4 DNA Ligase (NEB, M0202) was added and incubated at room temperature for 4 hours with slow rotation. Hi-C material was sheared to a size of 300-500bp using a Covaris instrument (Covaris S2, Woburn, MA). Biotin-tagged DNA was pulled down using Dynabeads MyOne Streptavidin C1 beads (Life technologies, 65002) with 2X Binding Buffer (2X BB: 10mM Tris-HCl (pH 7.5), 1nM EDTA, 2M NaCl).
ChIP assays were performed in C42B, 22Rv1 and RWPE1 cells using H3K9me3 (Cat# 13969 Lot# 1, Cell Signaling and Technology, Inc.), H3K27me3 (Cat# 9733 Lot# 8, Cell Signaling and Technology, Inc.), and H3K36me3 (Cat# 2901 Lot# 3, Cell Signaling and Technology, Inc.) antibodies, according to ENCODE standards (
RNA-seq was performed in triplicate for RWPE1, C42B, and 22Rv1 cells. RNA was extracted using Trizol reagent (Cat # 15596-018, Thermo Fisher Scientific, NY, USA) and the quality of RNA was assessed using a 2100 Bioanalyzer instrument (Cat # G2939AA, Agilent technologies), as described previously.
For NOMe-seq, after isolating nuclei from the cells, M.CviPI was treated to methylate accessible GpCs. After purifying M.CvPI-treated DNA, sonication was performed. Bisulfite treatment of M.CviPI-methylated DNA resulted to convert all unmethylated Cs to Ts.
In situ Hi-C ibraries were prepared using Kapa Hyper prep kit (Kapa #KK8503) according to the provided protocol. Library was amplified with PCR using Illumina primers.
ChIP-seq: Libraries were barcoded (NEXTflex™ DNA Barcodes) (Bio Scientific, Austin, TX).
RNA-seq libraries were made using KAPA Stranded mRNA-Seq Kit with KAPA mRNA Capture Beads (KK8420) (Kapa Biosystems, Woburn, MA).
NOMe-seq: Libraries were generated using the Accel-NGS Methyl-Seq DNA Library Kit for Illumina Platforms.
Library strategy Hi-C
Library source genomic
Library selection other
Instrument model Illumina HiSeq 2000
Data processing The quality of each in situ Hi-C library was checked with FastQC and HIC-Pro version 2.8.0. Raw fastq files were processed through the HiC-Pro version 2.8.0 to make the raw contact count matrices for multiple resolutions. The matrices were normalized using the iterative correction method (iced python library). To increase the sequencing depth, replicates were pooled and processed as above described.
Each ChIP-seq experiment was performed in duplicate and ChIP-seq libraries were sequenced on an Illumina Hiseq machine. All ChIP-seq data were mapped to hg19 and peaks were called using MACS245 after preprocessing data with the ENCODE3 ChIP-seq pipeline ( To call reproducible peaks from two replicates, the naïve overlap tool for histone mark datasets was used, as suggested in the ENCODE3 ChIP-seq standards document ( and previously described.
For RNA-seq, reads were mapped to hg19 GENCODE version 19 using STAR 2.4.1d49 and aligned reads were quantified at the gene level using Partek® Flow® software Quantify to annotation model (Partek Inc., St. Louis, MO, USA). The RPKM normalization method was used and log2 transformed. Differentially expressed genes between normal and cancer cells were selected by using the Gene Specific Algorithm from Partek® Flow® software using the upper quartile normalization method (Partek Inc., St. Louis, MO, USA) (FDR <0.05).
For NOMe-seq, the fastq files were aligned to a bisulfite-converted genome using the BSMAP, and the Bis-SNP was used to call methylation sites. NDR was called using the findNDRs function from the aaRon R package ( (P-value cutoff, 1e-8).
Genome_build: GRCh37
For in situ Hi-C, text files include contact count matrices at 10kb and 40kb, respectively
For ChIP-seq, tab-delimited text files include location of peaks
For RNA-seq, tab-delimited text files include log2(RPKM+1) for each gene.
For NOMe-seq, tab-delimited text files include location of nucleosome depleted regions
Submission date Jan 15, 2019
Last update date Sep 13, 2019
Contact name Suhn K Rhie
Organization name University of Southern California
Street address 1450 Biggy Street
City Los Angeles
State/province CA
ZIP/Postal code 90089
Country USA
Platform ID GPL11154
Series (1)
GSE118629 A prostate cancer chromatin interaction map
BioSample SAMN10754012
SRA SRX5253425

Supplementary file Size Download File type/resource
GSM3564252_RWPE1_HiC_10k.normalized.matrix.txt.gz 1.3 Gb (ftp)(http) TXT
GSM3564252_RWPE1_HiC_10k.raw.matrix.txt.gz 555.2 Mb (ftp)(http) TXT
GSM3564252_RWPE1_HiC_40k.normalized.matrix.txt.gz 779.5 Mb (ftp)(http) TXT
GSM3564252_RWPE1_HiC_40k.raw.matrix.txt.gz 315.4 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap